This activity is supported by an educational donation provided by Amgen.



Osteoporosis Compendium
  1. Course List
Co-Chairs
faculty image
Jeffrey P. Levine, MD, MPH
  • Associate Professor
  • Director of Women's Health Programs
  • Department of Family Medicine
  • UMDNJ-Robert Wood Johnson Medical School
  • New Brunswick, New Jersey
    • faculty image
    Marjorie M. Luckey, MD
  • Medical Director
  • Osteoporosis Center
  • Saint Barnabas Medical Center
  • Livingston, New Jersey
    • faculty image
    Ethel S. Siris, MD
  • Madeline C. Stabile Professor of Clinical Medicine
  • Director
  • Toni Stabile Osteoporosis Center
  • Columbia University Medical Center
  • New York-Presbyterian Hospital
  • New York, New York
    • This program is developed by Projects In Knowledge and endorsed by The Endocrine Society, a prominent international organization which advocates for early diagnosis of osteoporosis for fracture prevention. This collaboration brings an in-depth access to the Endocrine Society's osteoporosis practice guidelines and background issues associated with them.
    The Osteoporosis Compendium features
    • Diagnostic methods used to screen for osteoporosis and osteoporosis-associated fractures
    • Practice guidelines
    • Current and emerging treatment strategies

  • Assess risk factors and disease burden associated with the development of osteoporosis and fractures, as well as diagnostic methodology to improve screening and diagnosis of osteoporosis/fractures.
  • Evaluate the bone remodeling process to determine the impact of resorptive/catabolic pathways (eg, RANK-L/RANK/OPG) and anabolic pathways (eg, Wnt signaling pathways) on osteoporosis and fractures.
  • Analyze how current and emerging osteoporosis and fracture prevention therapies impact the pathophysiology of bone health to reduce fracture risk through an understanding of the mechanism of action of antiresorptive/anticatabolic agents, anabolic agents, and dual-action bone agents.
  • Formulate successful osteoporosis and fracture prevention and treatment regimens that include current antiresorptive/anticatabolic and anabolic agents based on an analysis of the efficacy, safety, dosing, and administration of these therapies, and side effect management.
  • Assess the potential role of emerging osteoporosis and fracture prevention and treatment regimens—including antiresorptive/anticatabolic agents, anabolic agents, and dual action bone agents—in patients at risk for or with osteoporosis, when these agents are approved by the FDA.
    • Bisphosphonates
      • Alendronate (and alendronate plus vitamin D)
      • Risedronate (and risedronate plus calcium)
      • Ibandronate
      • Zoledronic acid
      • Etidronate
      • Pamidronate
      • Tiludronate
    • Calcitonin
    • Selective estrogen receptor modulators (SERMs)
      • Raloxifene
      • Lasofoxifene
      • Bazedoxifene
      • Ospemifene
      • Arzoxifene
    • Cathepsin K inhibitors
      • Odanacatib
    • RANKL binding compounds
      • Denosumab
    Anabolic agents
    • Parathyroid hormone (PTH) analogs
      • Teriparatide
      • Full-length PTH
    • Calcium-sensing receptor antagonists
      • Ronacaleret
      • ATF936
    • Strontium ranelate
    • Tibolone
    • Assessing fracture risk
      • How to quickly identify patients at risk
      • How to screen
      • What laboratory tests are needed
      • New tool from WHO for treatment decisions
    • How to use bone density results in clinical practice
    • High-risk medication and disease—which of your patients are at risk?
    • FAQs: How long to treat? Osteonecrosis of the jaw? Monitoring? When to change therapy?

    Target Audience

    These activities are designed for primary care physicians, including internists, family practitioners, gynecologists, rheumatologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

     

    Activity Goal

    The goal of these CME/CE activities is to address gaps in competence and practice performance by:

    • Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
    • Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
    • Providing updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, and their role in providing fracture prevention/reduction
    • Monitoring therapy for efficacy and safety, and take steps to ensure or improve compliance
    • Providing online patient education materials